Population-based study of long-term survival in patients with clinically localised prostate cancer

Lancet

Volumn 349, Issue 9056, 1997, Pages 906-910

  Lu Yao, Grace L ^a   Yao, Siu Long ^b  

^a CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT PLANNING;

EID: 0030891731     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09380-4     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
2. Scardino P. Problem of prostate cancer. J Urol 1994; 152: 1677-78.
3. Wasson J, Cushman C, Bruskewitz R, et al. A structured literature review of treatment for localized prostate cancer. Arch Family Med 1993; 2: 487-93.
4. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1910-14.
5. Norlén BJ. Swedish randomized trial of radical prostatectomy versus watchful waiting. Can J Oncol 1994; 4 (suppl): 38-40.
6. Austenfeld MS, Thompson IM, Middleston RG. Meta-analysis of the literature: guideline development for prostate cancer treatment. J Urol 1994; 152: 1866-69.
7. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995; 154: 2144-48.
8. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-36.
9. Zinche H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-57.
10. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995; 32: 287-92.
11. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994; 152: 1781-85.
12. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Osterling J. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Urology 1995; 46: 2-13.
13. Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205-12.
14. Surveillance Epidemiology and End Results Program. Case diagnosed in 1973-1992, public-use database. Bethesda, MD: National Cancer Institute, 1995.
15. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 11: 58-64.
16. Zincke H, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994; 12: 2254-63.
17. Johansson J-E, Adami H-O, Andersson SO, Bergstrom R, Holmberg L, Krusenmo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-96.
18. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-48.
19. Fleming C, Wasson J, Albertsen P, Barry M, Wennberg JE. Prostate PORT: a decision analysis of alternative treatment for clinically localized prostate cancer. JAMA 1993; 269: 2650-58.
20. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152: 1894-99.
21. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer-multi-institutional pooled analysis. JAMA 1996; 276: 615-19.
22. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-48.
23. Horm JW, Asire AJ, Young JLJ. Surveillance, Epidemiology, and End Results Program: cancer incidence and mortality in the United States, 1973-91. Bethesda, MD: National Cancer Institute, 1984.
24. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981; 71: 242-50.
25. Shambaugh EM, Weiss MA. Summary staging guide for the Cancer Surveillance, Epidemiology and End Results Reporting (SEER) Program: US Department of Health and Human Services Public Health Service National Institutes of Health, 1986.
26. American Joint Committee on Cancer. Manual for staging of cancer, 4th edn. Philadelphia: Lipponcott, 1992.
27. Bell FC, Wade AH, Goss SC. Life tables for the United States Social Security Area 1900-2080. Baltimore: Social Security Administration, 1992.
28. Middleton RG. The management of clinically localized prostate cancer: guidelines from the American Urological Association. CA Cancer J Clin 1996; 46: 249-53.
29. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127-32.
30. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Find J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31.